Pregnant women may get safer HIV protection with tailored PrEP doses
NCT ID NCT06435026
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested three different daily doses of the HIV prevention pill PrEP in 54 pregnant women in Sub-Saharan Africa. The goal was to find the dose that gives the best protection without harming the mother or baby. Researchers measured drug levels in the blood and tracked any side effects. The results will help guide safer HIV prevention during pregnancy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) - a daily pill to prevent HIV
What this could lead to
If successful, this could lead to better HIV prevention guidelines for pregnant women, reducing mother-to-child transmission.
What could go wrong
This is a small, early-stage study (54 participants) focused on drug levels and safety, not on actual HIV prevention. Higher doses may cause more side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREGNANCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bwaila District Hospital
Lilongwe, Malawi
-
Seke North CRS
Harare, Zimbabwe